Literature DB >> 20018266

Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.

J Wayne Conlan1, Hua Shen, Igor Golovliov, Carl Zingmark, Petra C F Oyston, Wangxue Chen, Robert V House, Anders Sjöstedt.   

Abstract

Francisella tularensis subspecies tularensis is a highly virulent facultative intracellular pathogen of humans and a potential biological weapon. A live vaccine strain, F. tularensis LVS, was developed more than 50 years ago by pragmatic attenuation of a strain of the less virulent holarctica subspecies. LVS was demonstrated to be highly effective in human volunteers who were exposed to intradermal challenge with fully virulent subsp. tularensis, but was less effective against aerosol exposure. LVS faces regulatory hurdles that to date have prevented its licensure for general use. Therefore, a better defined and more effective vaccine is being sought. To this end we have created gene deletion mutants in the virulent subsp. tularensis strain and tested them for their ability to elicit a protective immune response against systemic or aerosol challenge with the highly virulent wild-type subsp. tularensis strain, SCHU S4. Both oral and intradermal (ID) primary vaccination routes were assessed in BALB/c and C3H/HeN mice as was oral boosting. One SCHU S4 mutant missing the heat shock gene, clpB, was significantly more attenuated than LVS whereas a double deletion mutant missing genes FTT0918 and capB was as attenuated as LVS. In general mice immunized with SCHU S4DeltaclpB were significantly better protected against aerosol challenge than mice immunized with LVS. A single ID immunization of BALB/c mice with SCHU S4DeltaclpB was at least as effective as any other regimen examined. Mice immunized with SCHU S4Delta0918DeltacapB were generally protected to a similar degree as mice immunized with LVS. A preliminary examination of immune responses to vaccination with LVS, SCHU S4DeltaclpB, or SCHU S4Delta0918DeltacapB provided no obvious correlate to their relative efficacies. Crown Copyright (c) 2009. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018266      PMCID: PMC2822029          DOI: 10.1016/j.vaccine.2009.12.001

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  41 in total

1.  Aerogenic immunization of the monkey and guinea pig with live tularemia vaccine.

Authors:  H T EIGELSBACH; J J TULIS; E L OVERHOLT; W R GRIFFITH
Journal:  Proc Soc Exp Biol Med       Date:  1961-12

Review 2.  Salmonella vaccines for use in humans: present and future perspectives.

Authors:  Helen S Garmory; Katherine A Brown; Richard W Titball
Journal:  FEMS Microbiol Rev       Date:  2002-11       Impact factor: 16.408

3.  Cell-mediated resistance to aerogenic infection of the lung.

Authors:  G L Truitt; G B Mackaness
Journal:  Am Rev Respir Dis       Date:  1971-12

4.  Aerogenic immunization of man with live Tularemia vaccine.

Authors:  R B Hornick; H T Eigelsbach
Journal:  Bacteriol Rev       Date:  1966-09

5.  Comparative pre-clinical and clinical experience with oral polio vaccine produced on MRC-5 cells or on primary monkey kidney cells.

Authors:  Viktor Prikazsky; Geert Leroux-Roels; Pierre Van Damme; Assad Safary; Brigitte Colau; Michel Duchene
Journal:  Vaccine       Date:  2005-07-21       Impact factor: 3.641

6.  Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.

Authors:  J Wayne Conlan; Hua Shen; Rhonda Kuolee; Xigeng Zhao; Wangxue Chen
Journal:  Vaccine       Date:  2005-03-31       Impact factor: 3.641

7.  Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.

Authors:  Heather J Ray; Yu Cong; Ashlesh K Murthy; Dale M Selby; Karl E Klose; Jeffrey R Barker; M Neal Guentzel; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2009-02-11

Review 8.  Animal models of Francisella tularensis infection.

Authors:  C Rick Lyons; Terry H Wu
Journal:  Ann N Y Acad Sci       Date:  2007-03-29       Impact factor: 5.691

9.  An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes.

Authors:  Marcela F Pasetti; Lilian Cuberos; Thomas L Horn; Jeffry D Shearer; Stephen J Matthews; Robert V House; Marcelo B Sztein
Journal:  Vaccine       Date:  2008-01-29       Impact factor: 3.641

10.  Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A Francisella tularensis.

Authors:  J Wayne Conlan; Xigeng Zhao; Gregory Harris; Hua Shen; Mark Bolanowski; Cecilia Rietz; Anders Sjostedt; Wangxue Chen
Journal:  Mol Immunol       Date:  2008-03-05       Impact factor: 4.407

View more
  38 in total

1.  A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.

Authors:  Qingmei Jia; Bai-Yu Lee; Richard Bowen; Barbara Jane Dillon; Susan M Som; Marcus A Horwitz
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

2.  A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.

Authors:  Qingmei Jia; Richard Bowen; Jacob Sahakian; Barbara Jane Dillon; Marcus A Horwitz
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

3.  A Francisella tularensis locus required for spermine responsiveness is necessary for virulence.

Authors:  Brian C Russo; Joseph Horzempa; Dawn M O'Dee; Deanna M Schmitt; Matthew J Brown; Paul E Carlson; Ramnik J Xavier; Gerard J Nau
Journal:  Infect Immun       Date:  2011-06-13       Impact factor: 3.441

4.  Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.

Authors:  Katharina Richard; Barbara J Mann; Lenea Stocker; Eileen M Barry; Aiping Qin; Leah E Cole; Matthew T Hurley; Robert K Ernst; Suzanne M Michalek; Daniel C Stein; Philip Deshong; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

5.  Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain.

Authors:  Douglas S Reed; Le'kneitah P Smith; Kelly Stefano Cole; Araceli E Santiago; Barbara J Mann; Eileen M Barry
Journal:  Infect Immun       Date:  2014-03-10       Impact factor: 3.441

6.  Members of the Francisella tularensis phagosomal transporter subfamily of major facilitator superfamily transporters are critical for pathogenesis.

Authors:  Mark E Marohn; Araceli E Santiago; Kari Ann Shirey; Michael Lipsky; Stefanie N Vogel; Eileen M Barry
Journal:  Infect Immun       Date:  2012-04-16       Impact factor: 3.441

7.  Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.

Authors:  Qingmei Jia; Richard Bowen; Bai-Yu Lee; Barbara Jane Dillon; Saša Masleša-Galić; Marcus A Horwitz
Journal:  Vaccine       Date:  2016-08-28       Impact factor: 3.641

8.  Infection with Francisella tularensis LVS clpB leads to an altered yet protective immune response.

Authors:  Lydia M Barrigan; Shraddha Tuladhar; Jason C Brunton; Matthew D Woolard; Ching-ju Chen; Divey Saini; Richard Frothingham; Gregory D Sempowski; Thomas H Kawula; Jeffrey A Frelinger
Journal:  Infect Immun       Date:  2013-03-25       Impact factor: 3.441

9.  Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy.

Authors:  Hua Shen; Gregory Harris; Wangxue Chen; Anders Sjostedt; Patrik Ryden; Wayne Conlan
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

Review 10.  Live attenuated tularemia vaccines: recent developments and future goals.

Authors:  Mark E Marohn; Eileen M Barry
Journal:  Vaccine       Date:  2013-06-10       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.